Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma

Molecular Cancer Therapeutics

Volumn 5, Issue 6, 2006, Pages 1423-1433

  Flynn, Janet ^a   Berg, Randal W ^a,b   Wong, Tracy ^a,b   van Aken, Marijke ^c   Vincent, Mark D ^a,b   Fukushima, Masakazu ^d   Koropatnick, James ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c UTRECHT UNIVERSITY   (Netherlands)

^d TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; BETA GALACTOSIDASE; CASPASE INHIBITOR; MESSENGER RNA; THYMIDYLATE SYNTHASE;

APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN MCF 7; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; EXPRESSION VECTOR; FLOW CYTOMETRY; GENETIC TRANSFECTION; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; IC 50; IMMUNOCHEMISTRY; IN SITU HYBRIDIZATION; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; SURVIVAL RATE; UTERINE CERVIX CARCINOMA;

AGED; APOPTOSIS; CELL PROLIFERATION; DOWN-REGULATION; FLOW CYTOMETRY; HELA CELLS; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MIDDLE AGED; OLIGONUCLEOTIDES, ANTISENSE; RNA, MESSENGER; THYMIDYLATE SYNTHASE;

EID: 33746067150     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0073     Document Type: Article

References (40)

1. Carbone M, Rdzanek MA. Pathogenesis of malignant mesothelioma. Clin Lung Cancer 2004;5 Suppl 2:S46-50.
2. Weill H, Hughes J, Churg A. Changing trends in US mesothelioma incidence. Occup Environ Med 2005;62:270.
3. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-603.
4. O'Brien ME. Malignant mesothelioma - the UK experience. Lung Cancer 2004;45 Suppl 1:S133-5.
5. Niklinski J, Niklinska W, Chyczewska E, et al. The epidemiology of asbestos-related diseases. Lung Cancer 2004;45 Suppl 1:S7-15.
6. Van Gelder T, Damhuis RA, Hoogsteden HC. Prognostic factors and survival in malignant pleural mesothelioma. Eur Respir J 1994;7: 1035-8.
7. Ball DL, Cruickshank DG. The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy. Am J Clin Oncol 1990;13:4-9.
8. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 1991;102:1-9.
9. Tomek S, Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Lung Cancer 2004;45 Suppl 1:S103-19.
10. Zangemeister-Wittke U, Hopkins-Donaldson S. Apoptosis regulation and drug resistance in malignant pleural mesothelioma. Lung Cancer 2005;49 Suppl 1:S105-8.
11. Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002;38:111-21.
12. Fizazi K, Caliandro R, Soulie P, et al. Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma. Eur J Cancer 2000;36:1514-21.
13. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23:6881-9.
14. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21: 2636-44.
15. Carreras CW, Santi DV. The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 1995;64:721-62.
16. Bollag W. Experimental studies on 5-fluorouracil, a cytostatic agent. Schweiz Med Wochenschr 1957;87:817-20.
17. Haggmark A. Studies on resistance against 5-fluorouracil. II. Thymidylate synthetase from drug-resistant tumor lines. Cancer Res 1962;22:568-72.
18. Costi MP, Ferrari S, Venturelli A, Calo S, Tondi D, Barlocco D. Thymidylate synthase structure, function and implication in drug discovery. Curr Med Chem 2005;12:2241-58.
19. Chu E, Cogliati T, Copur SM, et al. Identification of in vivo target RNA sequences bound by thymidylate synthase. Nucleic Acids Res 1996;24: 3222-8.
20. Rahman L, Voeller D, Rahman M, et al. Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 2004;5:341-51.
21. Ferguson PJ, Collins O, Dean NM, et al. Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol 1999;127: 1777-86.
22. Ferguson PJ, DeMoor JM, Vincent MD, Koropatnick J. Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cells. Br J Pharmacol 2001;134: 1437-46.
23. 2-M cell cycle arrest induced by antisense oligodeoxynucleotide targeting thymidylate synthase. J Pharmacol Exp Ther 2001;298: 477-84.
24. Schmitz JC, Chen TM, Chu E. Small interfering double-stranded RNAs as therapeutic molecules to restore chemosensitivity to thymidylate synthase inhibitor compounds. Cancer Res 2004;64:1431-5.
25. Schmitz JC, Yu D, Agrawal S, Chu E. Effect of 2′-O-methyl antisense ORNs on expression of thymidylate synthase in human colon cancer RKO cells. Nucleic Acids Res 2001;29:415-22.
26. Stein CA, Cohen JS. Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res 1988;48:2659-68.
27. Geary RS, Yu RZ, Levin AA. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Investig Drugs 2001;2: 562-73.
28. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;184:39-51.
29. Polverino AJ, Patterson SD. Selective activation of caspases during apoptotic induction in HL-60 cells. Effects of a tetrapeptide inhibitor. J Biol Chem 1997;272:7013-21.
30. Berg RW, Ferguson PJ, Vincent MID, Koropatnick DJ, A "combination oligonucleotide" antisense strategy to clownregulate thymidylate synthase and decrease tumor cell growth and drug resistance. Cancer Gene Ther 2003;10:278-86.
31. Kindler HL, Herndon JE, Zhang C, Green MR. Irinotecan for malignant mesothelioma. A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2005;48:423-8.
32. Belani CP, Adak S, Aisner S, Stella PJ, Levitan N, Johnson DH. Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group. Clin Lung Cancer 2004;6:43-7.
33. Porta C, Zimatore M, Bonomi L, et al. Raltitrexed-oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer 2005;48:429-34.
34. Marzo AL, Fitzpatrick DR, Robinson BW, Scott B. Antisense oligonucleotides specific for transforming growth factor β2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 1997;57:3200-7.
35. Gordon GJ, Appasani K, Parcells JP, et al. Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma. Carcinogenesis 2002;23:1017-24.
36. Xia C, Xu Z, Yuan X, et al. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther 2002; 1:687-94.
37. Smythe WR, Mohuiddin I, Ozveran M, Cao XX. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product. J Thorac Cardiovasc Surg 2002;123:1191-8.
38. McClean S, Robinson RC, Shaw C, Smyth WF. Characterisation and determination of indole alkaloids in frog-skin secretions by electrospray ionisation ion trap mass spectrometry. Rapid Commun Mass Spectrom 2002;16:346-54.
39. Berg RW, Ferguso PJ, DeMoor JM, Vincen MD, Koropatnick J. The means to an end of tumor cell resistance to chemotherapeutic drugs targeting thymidylate synthase: shoot the messenger. Curr Drug Targets 2002;3:297-309.
40. Jason TL, Koropatnick J, Berg RW. Toxicology of antisense therapeutics. Toxicol Appl Pharmacol 2004;201:66-83.